---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-001140"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2025-01-03T23:59:59+00:00"
generated_at: "2026-05-28T15:01:22.182562+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tivic Health receives Nasdaq delisting notice; hearing requested, reverse split proposed

## Summary
- Nasdaq notified Tivic on Dec 27, 2024 it failed to regain $1.00 bid price compliance and is ineligible for a second 180-day period due to equity deficiency.
- Company requested a hearing on Jan 3, 2025, which automatically stays any suspension or delisting pending the hearing and Panel decision.
- Special stockholder meeting set for Jan 31, 2025 to vote on reverse stock split (ratio 1:2 to 1:30) to regain bid price compliance.
- No assurance that the company will regain compliance or that the Nasdaq Panel will grant continued listing.

## SEC filing metadata
- accession: 0000950170-25-001140
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2025-01-03T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017025001140/0000950170-25-001140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017025001140/tivc-20241227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-001140
- JSON: https://secwatch.observer/filing/0000950170-25-001140.json
- Plain text: https://secwatch.observer/filing/0000950170-25-001140.txt

## Key facts
- Listing & Compliance Notices
  Valion Bio, Inc. received a nasdaq delisting notice notice regarding stockholders equity.
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: stockholders equity
  source text: December 27, 2024, the Company received an additional letter from Nasdaq, notifying the Company that it has not regained compliance with the Rule and is not eligible for a second 180-day remediation period. Specifically
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000095017025001140/0000950170-25-001140-index.htm
- Listing & Compliance Notices
  Valion Bio, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: December 27, 2024, the Company received an additional letter from Nasdaq, notifying the Company that it has not regained compliance with the Rule and is not eligible for a second 180-day remediation period. Specifically
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000095017025001140/0000950170-25-001140-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.